Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical Dermatology Conference - January 17 - 22 Business Wire KONA COAST, Hawaii & IRVINGTON, N.Y. -- January 16, 2014 MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind^®, an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored Clinical Advisory meeting for select dermatologists and key opinion leaders in melanoma and provide recent clinical findings at the Winter Clinical Dermatology Conference being held January 17-22 at the Fairmont Orchid Hotel, Kona Coast, Hawaii. MELA Sciences’ Clinical Advisory meeting, for current and prospective MelaFind^® users and thought leaders, will discuss technical advancements for the MelaFind^® device as well as opportunities for future technology development for the Company’s optical imaging and analysis technologies. Dr. Darrell Rigel, Clinical Professor of Dermatology at New York University Medical Center, will moderate the meeting and Dr. Monica Scheel of Kailua Kona, HI will present her real world experience with MelaFind^® and discuss its integration into her practice. The Winter Clinical is expected to have over 400 dermatologists in attendance. Practicing dermatologists will engage in comprehensive updates and dialogue on the diagnosis and treatment of a variety of medical, surgical and appearance dermatology conditions led by leading dermatologists from the U.S. and Canada. MELA Sciences will exhibit four poster presentations focused on the use of MelaFind^®, its multispectral digital skin lesion analysis tool. The posters review clinical data from practice and clinical settings, using MelaFind^® in the assessment of pigmented skin lesions in a variety of patients including young adults and those with atypical mole syndrome. According to the Melanoma Research Foundation people under 30 are developing melanoma at an alarming rate, with the incidence rising by 50% in young women since 1980. It is the most common form of cancer for young adults aged 25-29 and the second most common cancer in adolescents and young adults aged 15-29. MelaFind^® is the first and only FDA-approved and CE Mark-approved optical imaging device for use by dermatologists in the detection and analysis of melanoma. The Cleveland Clinic recognized it as a Top 10 Medical Innovation for 2013. Click here for additional information about MelaFind^®. Please follow us: Twitter: @MELASciencesIR or @MelaFind StockTwits: @MELASciencesIR Facebook: www.facebook.com/MelaFind About MELA Sciences, Inc. www.melasciences.com MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's cell structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms. Contact: Media MELA Sciences, Inc. Diana Garcia Redruello, 212-518-4226 firstname.lastname@example.org or Investors Catalyst Global Toni Trigiani, David Collins, 212-924-9800 email@example.com
Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical
Press spacebar to pause and continue. Press esc to stop.